153
Participants
Start Date
May 8, 2017
Primary Completion Date
August 15, 2025
Study Completion Date
November 30, 2025
Pritelivir
100 mg oral tablets
Investigator's choice
Foscarnet iv, 40 mg/kg BW tid or 60mg/kg bid or Cidofovir iv, 5 mg/kg BW given once weekly or Cidofovir 1% or 3%, topically applied 2 to 4 times daily or Imiquimod 5%, Solution for iv infusion or topical application
Hopitaux universitaires de Geneve, Geneva
Westmead Hospital, Centre for Infectious Disease and Microbiology, Westmead
Melbourne Health - Royal Melbourne Hospital, Parkville
Universitaetsspital Basel, Basel
Hospital Rawson, Córdoba
Sanatorio Mayo Privado S.A., Córdoba
AZ Sint-Jan Brugge, Bruges
Universitaetsspital Zuerich, Zurich
AZ Delta, Roeselare
David H. Koch Center at Memorial Sloan Kettering Cancer Center, New York
Kings Country Hospital Center, Brooklyn
General Hospital of Athens - Laiko, Athens
University of Pittsburgh Medical Center, Pittsburgh
Penn State Health Milton S. Hershey Medical Center, Hershey
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milan
Johns Hopkins University School of Medicine, Baltimore
Fondazione IRCCS Policlinico San Matteo, Pavia
Atrium Health Wake Forest Baptist, Winston-Salem
Duke University Medical Center - Division of Infectious Diseases, Durham
Metro Infectious Disease Consultants - Atlanta, Decatur
Emory Hospital Midtown Infectious Disease Clinic, Atlanta
University of Florida (UF) - Division of Infectious Disease, Gainesville
Midland Florida Clinical Research Center, LLC, DeLand
Links Clinical Trials, Miami
University of South Florida, Tampa
Instituto de Investigaciones Aplicadas a la Neurociencia A.C, Durango
Midway Immunology and Research Center (MIRC), Ft. Pierce
University of Alabama at Birmingham, Birmingham
Metro Infectious Disease Consultants, LLC - Huntsville, Hunstville
University of South Alabama, Mobile
CHU de Nantes, Nantes
Centro de Investigacion Farmaceutica Especializado de Occidente S.C., Guadalajara
Universitätsklinikum Essen, Essen
Cincinnati Children's Hospital Medical Center, Cincinnati
Universitätsklinikum Köln, Cologne
University of Minnesota, Minneapolis
Metro Infectious Disease Consultants, LLC, Burr Ridge
Department of Medicine J. H. Stroger Hospital of Cook County, Chicago
Lee's Summit MO United States 64086, Lee's Summit
Unidad de Investigacion CIMA SC, Chihuahua City
University of Nebraska Medical Center, Omaha
Tulane University - School of Medicine, New Orleans
LSU Health Baton Rouge Pulmonary Clinic, Baton Rouge
Regional University General Hospital of Heraklion, Heraklion
Hôpital Saint Louis - AP-HP, Paris
AP-HP Hopital Necker-Enfants Malades, Paris
AP-HP Hopital Bichat - Claude Bernard, Paris
University Arizona - Department of Medicine Arizona Health Sciences Center, Tuscon
CHU Limoges - Centre national de reference des Herpes virus, Limoges
"Grande Ospedale Metropolitano Bianchi Melacrino Morelli", Calabria
Cedars-Sinai Medical Center, Los Angeles
City of Hope, Duarte
Arke SMO S.A. de C.V., Veracruz
University of California, Division of Infectious Diseases, Sacramento
Universitätsklinikum Würzburg, Würzburg
Fred Hutchinson Cancer Research Center, Seattle
Chaim Sheba Medical Center, Tel Litwinsky
Brigham and Women's Hospital, Boston
Rutgers Robert Wood Johnson Medical School, New Brunswick
MD Anderson Cancer Center, Houston
Instituto FIDES, La Plata
Centre Hospitalier Universitaire Saint Pierre, Brussels
Alberta Health Services Cross Cancer Institute at the University of Alberta, Edmonton
LLC Diakor, Tbilisi
Multiprofile Clinic Consilium Medulla LTD, Tbilisi
Centro de Investigacion Clinica GRAMEL S.C., Distrito Federal
ARENSIA Exploratory Medicine LLC, Kyiv
Nhs Lothian, Edinburgh
Research Department of Haematology, UCL Cancer Institute, London
Freeman Hospital, Newcastle upon Tyne
Collaborators (1)
Medpace, Inc.
INDUSTRY
AiCuris Anti-infective Cures AG
INDUSTRY